NovoCure ( (NVCR) ) just unveiled an announcement.

Novocure reported a robust third quarter in 2024, with net revenues surging by 22% to $155 million, driven by successful market expansions and improved approval rates in the U.S. The company also celebrated FDA approval of Optune Lua for metastatic non-small cell lung cancer, marking a significant milestone. Additionally, management transitions are underway with Christoph Brackmann taking over as CFO from January 2025, as Novocure aims to sustain its growth and innovation in oncology treatment.

For a thorough assessment of NVCR stock, go to TipRanks’ Stock Analysis page.